Pro-Dex, Inc. (NASDAQ:PDEX – Get Free Report) Director Angelita Rebamontan Domingo sold 998 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $47.24, for a total transaction of $47,145.52. Following the sale, the director directly owned 18,779 shares in the company, valued at approximately $887,119.96. This trade represents a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Pro-Dex Price Performance
PDEX opened at $58.26 on Wednesday. The stock has a fifty day moving average of $62.18 and a 200-day moving average of $50.94. The firm has a market capitalization of $185.85 million, a P/E ratio of 16.09 and a beta of 0.01. Pro-Dex, Inc. has a 12-month low of $23.47 and a 12-month high of $68.99. The company has a quick ratio of 2.14, a current ratio of 3.67 and a debt-to-equity ratio of 0.32.
Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.58. The business had revenue of $19.95 million for the quarter, compared to the consensus estimate of $17.90 million. Pro-Dex had a return on equity of 22.78% and a net margin of 16.08%. Equities analysts forecast that Pro-Dex, Inc. will post 3.16 EPS for the current fiscal year.
Hedge Funds Weigh In On Pro-Dex
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on PDEX. Weiss Ratings raised shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. Wall Street Zen raised shares of Pro-Dex from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Zacks Research upgraded shares of Pro-Dex to a “hold” rating in a research note on Tuesday, May 19th. Finally, Ascendiant Capital Markets increased their target price on shares of Pro-Dex from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.00.
View Our Latest Analysis on Pro-Dex
About Pro-Dex
Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.
Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.
Featured Stories
- Five stocks we like better than Pro-Dex
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
